Zoono Group Limited has responded to an ASX price query following a recent surge in its share price and trading volume, confirming no undisclosed information exists and attributing market activity to ongoing shelf-life extension trials across multiple continents.
- Zoono denies any undisclosed material information explaining recent share price rise
- Price increased from $0.033 to $0.039 amid significant trading volume
- Ongoing shelf-life extension trials with OSY Group and global partners cited
- 45 trials across four continents covering diverse fresh produce and goods
- Company expects 5 to 6 major supply agreements within the next 12 months
Market Activity Triggers ASX Inquiry
On 17 October 2025, Zoono Group Limited (ASX, ZNO) addressed an official price query from ASX Compliance following an unusual uptick in its share price and trading volume. The company’s shares rose from a low of 3.3 cents on 9 October to 3.9 cents, accompanied by a notable surge in trading activity. Such movements prompted ASX to seek clarification on whether Zoono possessed any undisclosed material information that could explain the market behaviour.
No Undisclosed Information, Focus on Shelf-Life Extension Trials
Results to date have been positive, meeting the minimum shelf-life extension targets necessary for commercial viability, as outlined in Zoono’s FY25 Annual Report lodged in August 2025. The company reiterated its expectation to secure five to six significant supply agreements related to this project within the next 12 months, signaling potential commercial momentum ahead.
Compliance and Transparency Affirmed
Zoono confirmed full compliance with ASX Listing Rules, particularly continuous disclosure obligations under Listing Rule 3.1. The company’s response was authorised by its board, underscoring its commitment to transparency amid market speculation. While no new material announcements were made, the clarification aims to reassure investors that the recent price and volume changes are not driven by undisclosed developments.
Looking Ahead
Investors and market watchers will be keenly observing Zoono’s forthcoming announcements regarding trial outcomes and supply agreements. The company’s ability to convert promising trial results into commercial contracts could be a pivotal catalyst for its share price and market confidence. Meanwhile, the recent trading activity may reflect speculative interest or early positioning ahead of these anticipated developments.
Bottom Line?
Zoono’s next moves on supply agreements will be critical to sustaining investor confidence after this trading surge.
Questions in the middle?
- When will Zoono announce the expected supply agreements tied to its shelf-life extension project?
- How significant will the commercial impact of these agreements be on Zoono’s financial outlook?
- Could the recent trading activity signal insider anticipation or broader market speculation?